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ABSTRACT
A low prevalence of Parkinson’s disease (PD) has 
been reported in the Sub-Saharan Africa (SSA) re-
gion. The genetic causes and clinical features of PD 
in this region have been poorly described. Very few 
reports have examined the availability and access 
to evidence-based quality care for people living with 
PD in this region. We reviewed all publications fo-
cusing on idiopathic PD from SSA published up to 
May 2016 and observed a prevalence of PD ranging 
from 7/100,000 in Ethiopia to 67/100,000 in Nige-
ria. The most recent community-based study report-
ed a mean age at onset of 69.4 years. The infrequent 
occurrence of mutations in established PD genes 
was also observed in the region. Treatments were 
non-existent or at best irregular. Additionally, there is 
a lack of well-trained medical personnel and multi-
disciplinary teams in most countries in this region. 
Drugs for treating PD are either not available or un-
affordable. Large-scale genetic and epidemiological 
studies are therefore needed in SSA to provide fur-
ther insights into the roles of genetics and other eti-
ological factors in the pathogenesis of PD. The qual-
ity of care also requires urgent improvement to meet 
the basic level of care required by PD patients. 
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INTRODUCTION
Sub-Saharan Africa (SSA) is composed of Afri-
can countries south of the Sahara and consists of 47 
politically distinct states. SSA is one of the fastest 
growing regions of the world, with significant eco-
nomic growth in the past 10–15 years, which has re-
flected in a greater availability of and access to health 
facilities. However, most countries in the region are 
still below the World Health Organization (WHO) 
standard of one doctor per 100,000 population.1 The 
population of those with Parkinson’s disease (PD) in 
the SSA region is known to be relatively small. The 
low prevalence of PD in SSA may stem from several 
issues, including the relatively youthful population in 
SSA, with less than 5% of the total population above 
65 years; the fact that most cases of PD are not rec-
ognized partly because of the assumption that neu-
rological diseases are part of normal aging; and the 
scarcity of epidemiological studies in SSA.2
Key aspects of PD, such as the incidence and prev-
alence, genetic causes and clinical presentation, are 
poorly characterized in SSA.3 Few reports have ex-
amined the availability of and access to evidence-
based quality care for people living with PD in SSA 
countries. 
This review aims to accomplish the following:
1) Provide a descriptive summary of all epidemi-
ologic and genetic studies from SSA published up 
to May 2016.
2) Compare the genetic and epidemiologic re-
sults from SSA to those from other populations in 
Africa outside SSA. 
3) Review the level of care available and accessi-
ble to PD patients in SSA. 
MATERIALS & METHODS
Inclusion criteria
This review included all population-, outpatient 
clinic- and in-patient-based studies investigating 
epidemiologic, genetic or care-related aspects of PD 
in SSA up to May 2016. Only studies focusing on 
idiopathic PD using either the UK Parkinson Dis-
ease Society (UKPDS) brain bank4 or the WHO or 
Movement Disorders Society (MDS) diagnostic cri-
teria5 were included. 
Exclusion criteria
Only studies published in English were included. 
Articles on neurological inpatients or outpatients 
that did not focus on PD frequencies were exclud-
ed. We excluded review articles, with the exception 
of their references.
Search methods
Electronic searches
Electronic databases, such as MEDLINE and Af-
rican journals online, were used as the initial search 
resources. To include all relevant publications with-
in the scope of this review, the search was extended 
to include the following:
1) Reference lists of all review articles and prima-
ry studies available.
2) References found in abstract books of the Eu-
ropean Federation of Neurological Societies (EFNS), 
American Academy of Neurology (AAN), MDS, and 
Pan-African Association of Neurological Societies 
(PAANS).
3) References lists of relevant textbooks and cita-
tions of PD studies in Africa.
If articles investigating the treatment available for 
PD patients in SSA were not found in the initial 
search resources, the search was extended to include 
available WHO and World Bank data containing 
statistics on health care personnel and facilities in 
different regions of the world. Websites of the MDS 
Africa task force, patient support groups (Parkin-
son’s Disease Association) and professional organi-
zations (e.g., speech and language therapy and occu-
pational therapy) in Africa were also searched for 
available relevant services. Reports of PD-related 
services were also evaluated in this review. The flow 
diagram of the search process is shown in Figure 1.
Data collection and analysis
Study selection
The titles and abstracts obtained from the elec-
tronic database search were reviewed, and irrele-
vant studies were excluded. Full copies of the rele-
vant studies were obtained and reviewed in detail. 
Data extraction
Relevant information from the studies was ob-
tained using a data extraction sheet. The informa-
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tion sought included year of study, authors, country, 
setting of study, duration of study, year of publica-
tion, type of study, number of subjects, study de-
sign, characteristics of participants [age, gender, age 
at onset, duration of disease, Hoehn and Yahr rating, 
UPDRS (unified Parkinson’s disease rating scale) 
score, family history of PD], description of the study, 
and diagnostic criteria used. For prevalence studies, 
the crude prevalence and age-adjusted prevalence 
were recorded where available and reported as the 
number of patients per 100,000 persons. In the case 
of genetic studies, information regarding the genes 
studied, genetic mutations found, and the method 
for genetic analysis used was also extracted. Studies 
in other populations with similar characteristics 
were reviewed for prevalence statistics for compari-
son with those obtained in SSA. 
Data analysis
Data analysis was performed using Microsoft 
Excel, and the results are presented in the text, fig-
ures and tables.
RESULTS
We identified 11 genetic studies, 7 community-
based (door-to-door) prevalence studies and no in-
cidence studies in SSA populations. The genetic 
studies were all undertaken within the past decade. 
Regarding the distribution of genetic studies, 7 were 
from South Africa and 1 each was from Nigeria, 
Zambia and Ghana. One study6 included samples 
from the Human Diversity series extracted from dif-
ferent countries in SSA, including Nigeria, the Cen-
tral African Republic, the Democratic Republic of the 
Congo, Kenya, Namibia, Senegal and South Africa. 
The first genetic study was conducted by Okubadejo 
et al.,7 in which they screened 51 Nigerians with spo-
radic PD and an equal number of controls for muta-
tions in leucine-rich repeat kinase 2 (LRRK2), par-
kin (PRKN) and ataxin 3 (ATXN3). They concluded 
that pathogenic mutations in these genes were not 
common in Nigerians. Studies from South Africa 
examined mutations involving eukaryotic transla-
tion initiation factor 4GI (EIF4GI), vacuolar protein 
sorting 35 (VPS35), Parkin, microtubule-associat-
ed protein tau (MAPT), synuclein alpha interaction 
protein (SNCAIP), PTEN-induced putative kinase 1 
(PINK1), LRRK2, SNCA, PINK1, DJ-1, ubiquitin 
carboxyl-terminal esterase L1 (UCH-L1), ATP13A2, 
LPA, TNFSF9, CAV2, CAV1, and GCH1.8-12 These 
studies concluded that mutations in these genes are 
not a common cause of PD in the South African 
population. 
The Ghanaian study analyzed mutations in the 
LRRK2 gene, while that from Zambia screened all 
the SNCA, LRRK2, PINK1, DJ-1, and Parkin exons 
for any pathogenic mutations. Interestingly, these 
studies did not detect any pathogenic mutations 
among the indigenous black PD patients compared 
to other populations in which mutations in these 
genes have been associated with either sporadic or 
familial PD. The findings from these genetic studies 
are summarized in Table 1 and 2. 
The fact that these mutations were not observed 
in any of the genetic screens in SSA suggests that 
PD in SSA may have a unique genetic heritage. The 
genetic architecture of the indigenous people of SSA 
appears to be different from that of other popula-
tions outside Africa and in parts of Africa outside 
SSA. Despite the progress made in the past decade 
in PD genetics in SSA, it remains largely unexplored 
despite offering potentially one of the greatest diver-
sity of polymorphisms that can be studied in any re-
gion of the world.
Figure 1. Flow diagram of search process. *African 
journal online (AJOL) is a collection over 350 journals 
with focus on research from African academics. †articles 
excluded based on topic if the topic did not suggest the 
paper is focusing on epidemiology, genetics or care is-
sues in Sub-Saharan Africa. Those excluded based on 
abstract are those whose topic may suggest a focus 
that is relevant to the review but the abstract indicates it 
does not meet the inclusion criteria.
  167 articles from PubMed  +  47 articles from AJOL*
(91 excluded based on topic)       (34 excluded based 
                                                                   on topic†)
   76 PubMed articles  +  13 AJOL articles
(10 duplicates from AJOL and 47 others excluded after 
abstract review†)
30
full articles reviewed 
11 genetic / 7 community-based / 11 hospital-based 
reports / 1 region-wide survey
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Table 1. Genetic studies in SSA
S/N
Genetic mutation 
studied
Method of analysis Result(s) Sample size Country (Reference)
1 LRRK2, PRKN, ATXN3 Analyzed for common mutations 
using the Oragene kit for DNA 
extraction (DNA genotek)
No pathogenic mutations were found. 51 PD patients & 
51 controls
Nigeria 
(Okubadejo et al.7)
2 Parkin Single-strand conformation 
polymorphism analysis and the 
HRM* technique
•  Four disease-causing missense 
heterogeneous changes (H200Q, 
D280N, E310D, R4026)
•  Two homozygous exon deletions (exon 
3 & 4)
91 South Africa 
(Bardien et al.42)
3 LRRK2 HRM •  LRRK2 G2019S mutation found in 2 
patients
205 South Africa 
(Bardien et al.12)
4 SNCA, Parkin, PINK1, 
DJ-1, LRRK2, 
UCH-L1, ATP13A2
 MLPA† •  Exonic rearrangement in Parkin & 
SNCA in 7 (8%) patients
•  No exonic rearrangement in 4 genes 
(LRRK2, PINK1, DJ-1, & ATP13A2)
88 South Africa 
(Keyser et al.11)
5 PINK1 HRM technique & direct 
sequencing
•  Sixteen variants found:
- One homozygous mutation (Y258X)
-  Two heterozygous missense variants 
(P305A & E476K)
-  Thirteen polymorphisms, of which five 
were novel.
154 South Africa 
(Keyser et al.11)
6 MAPT, SNCAIP HRM method •  Two novel variants found for MAPT
•  One previously sequenced variant 
(E709Q) and three novel missense 
variants of SNCAIP
202 South Africa 
(Keyser et al.10)
7 E1F4G1‡ 
(NM_182917.3)
PCR amplified & sequenced •  EIF4G1 coding variants found in the 
SSA population were M290I, R305C, 
Y311C, P382L, E477K, & R1216H.
127 (SSA 
samples from 
the Human 
Diversity 
series)
Sample from the Central 
African Republic, the 
DR of the Congo, 
Kenya, Nigeria, 
Namibia, Senegal, and 
South Africa 
(Tucci et al.6)
8 SNCA, LRRK2, PINK1, 
DJ-1, Parkin
Direct sequencing •  Pathogenic mutation not detected in 
SNCA, PINK1 or DJ-1
•  Novel LRRK2 missense variant 
detected in one case
•  Two heterozygous likely disease-
causing deletions of Parkin (exon 2 & 
4) detected in early-onset cases
39 Zambia 
(Yonova-Doing et al.43)
9 Parkin HRM and MLPA •  Seven patients compound mutation in 
Parkin gene
•  Seven patients had heterozygous 
sequence variants
229 PD patients 
and ethically 
matched 
controls
South Africa 
(Haylett et al.9)
10 LRRK2 Direct sequencing LRRK2 exon 41 & 31 screening did not 
detect any mutations in all samples.
54 PD patients 
and 46 controls
Ghana 
(Cilia et al.53)
11 EIF4G1, VPS35‡ KASP genotyping assay No mutations found 418 PD patients 
& 528 controls
South Africa 
(Blanckenberg et al.3)
*HRM is a sequencing screening used to detect genetic variations due to processes such as mutation and polymorphisms, †MLPA is a technique used to detect 
exon dosage changes caused by genomic rearrangements, ‡E1F4GI and VPS35 are not among the well-established genetic causes of PD and have been sug-
gested to be involved in its etiology, MLPA: multiplex ligation-dependent-probe amplification, SSA: Sub-Saharan Africa, HRM, high-resolution melt, PD: Parkin-
son’s disease, KASP: kompetitive Allele Specific PCR, E1F4GI: eukaryotic translation initiation factor 4GI, VPS35: vacuolar protein sorting 35.
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Prevalence of PD in SSA
The first epidemiological studies on PD in SSA 
were undertaken in the 1980s in Nigeria, Ethiopia 
and Togo, and the most recent studies were commu-
nity-based prevalence studies from SSA, as summa-
rized in Table 3. The prevalence of PD in these stud-
ies ranged from 7/100,000 in Ethiopia to 67/100,000 
in Nigeria. Data from the World Bank regarding 
the estimated proportion of the country older than 
65 years at the times these studies were conducted 
are similar, suggesting a similarity in population 
structure in the different SSA countries studied.13 The 
first large-scale community-based prevalence study 
of PD was undertaken by Dotchin et al.14 This study 
investigated a population of 161,071 community 
dwellers using a two-stage procedure that involved 
6 initial screening sessions followed by an expand-
ed history and neurological examination of positive 
responders to confirm the diagnosis of PD. They uti-
lized the UKPDS brain bank criteria for the diagnosis 
of PD.4,15 The age-adjusted prevalence was 40/ 
100,000, which is lower than figures from Sweden 
and the United States, which were 76/100,000 and 
1036-2168/100,000, respectively.16,17
Hospital-based studies
Several clinic- and hospital-based studies have 
estimated the frequency of PD in SSA among med-
ical admissions, neurological admissions, or neu-
rology clinic attendants. Unlike community-based 
studies, most hospital-based series are recent surveys 
undertaken within the last 10 years. The hospital 
Table 2. Novel gene variants found in Sub-Saharan Africa studies
S/N Novel genetic variant(s)* Gene Country Reference
1 Heterozygous variant of PRKN (p.R334H and p.A46T) PRKN Nigeria Okubadejo et al.7
2 H200Q in exon 5 in a patient with a family history of PD
E310D in one patient with PD
Parkin South Africa Bardien et al.42
3 P305A variant reported in a female patient of a black Xhosa family with a positive family history 
of PD. Age at onset of 30 years.
PINK1 South Africa Keyser et al.11
4 Two novel variants found for MAPT reported in two patients. A91V in a male of mixed ancestry, with 
age at onset of 32 years. V6351 in a black male with age at onset of 60 years. 
Both variants predicted by PolyPhen as being benign variants.
MAPT South Africa Keyser et al.10
5 Novel LRRK2 missense (p.Ala1464Gly) of questionable pathological significance detected in one 
PD patient
LRRK2 Zambia Yonova-Doing et al.43
*novel variants-potential disease-causing mutations found in PD patients but not in controls. PD: Parkinson’s disease.
Table 3. Community-based (door-to-door) prevalence studies in Sub-Saharan Africa
S/N Country Year
Population size 
studied
Percentage of population 
> 65 years at the time 
of study*
Diagnostic criteria/ 
study procedure
Prevalence Reference
1 Nigeria 1982 20,000 rural community 
dwellers
3 WHO research protocol‡ 10/100,000 Osuntokun et al.54
2 Nigeria 1987 3,412 rural community 
dwellers
3 WHO research protocol 2/3,412 (0.1%)
Age-adjusted 
prevalence ratio = 
67/100,000
Schoenberg et al.55
3 Ethiopia 1986 to 
1988
60,820 community 
dwellers
3 Not stated 7/100,000 Tekle-Haimanot 
et al.56
4 Togo 1989 19,241 residing in two 
rural settings
3 WHO research protocol 20/100,000 Balogou et al.44
5 Tanzania 2003 16,647 rural community 3 UK PD Society Brain 
Bank Criteria†
Diagnosis of PD not 
confirmed in any of 
the patients
Winkler et al.31
6 Tanzania 2006 161,071 3 UK PD Society Brain 
Bank Criteria
33/100,000 Dotchin et al.14
*estimated proportion of people > 65 years at time of study was obtained from the World Bank data base records, World Bank, 2014, †UK PD brain bank criteria 
require the presence of bradykinesia plus at least one of rigidity, tremor or postural instability, ‡WHO protocol: This is a 2-stage procedure involving initial 
screening with a questionnaire followed by clinical examination by a specialist. PD: Parkinson’s disease.
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frequency depends on the setting in which it was 
estimated, as in-patient-based admission estimates 
are lower than ones from outpatient-based studies. 
Only two admission-based studies were identified. 
Talabi18 reported that PD accounted for 0.5% of all 
neurological admissions in a Nigerian hospital, 
while Lombard and Gelfand19 reported that PD was 
responsible for 0.02% of admissions among black 
populations in a Zimbabwean hospital between 1973 
and 1976. Outpatient-based studies reviewing hos-
pital records of consecutive referrals to neurology 
clinics provided estimates of PD frequency among 
neurology referrals or patients with Parkinsonism. 
The outpatient-based series and the estimated hospi-
tal frequency of PD studies and their references are 
summarized in Table 4.
Clinical characteristics of the different 
cohorts of patients studied in the sub-Saharan 
Africa studies
Dotchin et al.14 reported a mean age at disease 
onset of 69.4 years in the most recent community-
based population prevalence survey. The age of the 
patients at the time of these studies ranged from as 
young as 17 years, reported by Atadzhanov and 
Mwaba,20 to as old as 94 years, reported by Dotchin 
et al.14 These studies, in keeping with reports in 
other populations outside SSA, observed a male 
preponderance, with a male-to-female ratio rang-
ing from 1.2:1 to 4:1.
Evaluation of available care for PD patients 
in SSA
Evaluating the care of patients with PD in SSA is 
very challenging, as there are no systematic studies 
evaluating the care available or accessible to PD pa-
tients in this area. This review compares the avail-
ability of personnel, drugs and facilities in different 
settings to that recommended by standard guidelines 
such as the National Institute for Health and Care 
Excellence (NICE)21 or the Canadian guidelines for 
PD.22
Availability of standard management for PD 
patients in SSA 
Neurologists
The lack of neurologists and movement disorder 
specialists has made it difficult to diagnose and 
treat PD patients properly in SSA. Documented esti-
mates of country medical and neurological resources 
reported in the WHO atlas of country resources for 
neurological disorders23 and WHO reports1 indicate 
that there are 0.03 neurologists per 100,000 popula-
tion compared to 0.07 in South East Asia and 4.84 
per 100,000 population in Europe. Looking at the 
mean average of neurologists for all SSA countries 
does not portray the real deficiencies in the differ-
ent countries. A typical example is Malawi, where it 
was reported that until recently, there was only one 
part-time neurologist for a population of approxi-
Table 4. Outpatient clinic-based studies in Sub-Saharan Africa
S/N Country Year* Patient group studied Diagnostic criteria Hospital frequency Reference
1 Cameroon 2005–2011 
(6 yrs)
912 neurological consultations in the 
outpatient clinic
UK PD Society Brain 
Bank Criteria
2.96% of all neurology 
referrals
Tegueu et al.57
2 Cameroon 1993–2001 
(9 yrs)
84 patients referred to the outpatient clinic 
with degenerative brain disease
Same 48.8% of all patients referred 
with degenerative brain 
disease
Kengne et al.58
3 Ethiopia 2003–2004 
(1 yr)
720 neurological referrals to the outpatient 
clinic
NS† 7.2% of all neurological 
referrals to the outpatient 
clinic
Bower et al.34
4 Nigeria 1996–2006 
(10 yrs)
1,360 new referrals to the outpatient 
neurology clinic
UK PD Society Brain 
Bank Criteria
1.47% of all referrals to the 
clinic
Okubadejo et al.59
5 Tanzania 2002–2006 
(4 yrs)
1,908 consecutive referrals to the outpatient 
neurology clinic
UK PD Society Brain 
Bank Criteria
2.2% of all neurological 
referrals
Matuja and Aris60
6 Zambia 1999–2004 
(5 yrs)
163 patients who visited the OPD or were 
admitted with extrapyramidal symptoms
NS 31.3% of all referrals to 
neurology clinic or admitted 
to hospital with 
extrapyramidal symptoms
Atadzhanov and 
Mwaba20
*the duration of review varies between the different studies from 1 year to 10 years, †NS indicates that the diagnostic criteria were not clearly stated in the study 
concerned. PD: Parkinson’s disease.
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mately 12 million people.24
Moreover, the number of geriatricians was small 
in SSA, with over 30 countries having no undergrad-
uate or postgraduate geriatric training scheme .25
Parkinson’s disease nurses
PD is a new field of specialization in the region, 
as the first ever PD nurse training program in the 
region was led by Louise Ebenezer, a PD nurse spe-
cialist from the United Kingdom, in Tanzania in De-
cember 2012 with participating nurses from Rwanda, 
Uganda, Ethiopia, Kenya, Nigeria and Tanzania.26,27 
Subsequent courses have been held in Anglophone 
West Africa (Ghana 2013), Southern Africa (South 
Africa 2014) and Eastern Africa (Ethiopia in Janu-
ary 2016). WHO data show that there were no neu-
rology nurses as of 2006 in SSA per 100,000 popu-
lation compared to 0.005 in Southeast Asia, 0.13 in 
the Eastern Mediterranean, 0.14 in the Americas, 
0.32 in the Western Pacific and 2.43 in Europe per 
100,000 population at the same time.23
Speech-language therapist
The presence of speech-language therapist (SLT) 
services in each country from SSA was assessed to 
evaluate their availability. A search of the SSA re-
gional SLT website suggests that no SLT services 
have been registered in the following countries: Bu-
rundi, Burkina Faso, Cape Verde, Gambia, Guinea, 
Guinea Bissau, Liberia, Mali, Niger and Sierra Leone.
SLT services are available in Kenya, Rwanda, Tan-
zania and Uganda in East Africa and in Cote d’Ivoire, 
Ghana, Nigeria, Senegal and Togo in West Africa; 
additionally, training is available at Kampala, Ugan-
da, and at several universities in South Africa, in-
cluding the university of Pretoria, Witwatersrand, 
Limpopo, Cape Town, and Stellenbosch.28
Occupational therapy and physiotherapy
No regional studies have evaluated the availabili-
ty or benefit of occupational therapy (OT)/physio-
therapy (PT) services among Africans with PD. Ac-
tive OT services are, however, currently registered 
in Botswana, Kenya, Malawi, Mauritius, Namibia, 
Nigeria, Rwanda, South Africa, Tanzania, Uganda, 
and Zimbabwe.29 For example, Nigeria had only 3 
registered occupational therapists out of 160 mil-
lion people.23 As of 2006, WHO data suggest that 
neuro-rehabilitation services are generally present in 
81.2% of countries in Africa.1 Dotchin et al.30 report-
ed that none of the PD patients reviewed in their 
series had visited a physiotherapist, while only one 
patient had seen an occupational therapist.
Availability of drugs
Most patients in SSA with PD do not have access 
to PD medication due to unavailability or, where 
available, financial constraints. PD drugs are avail-
able in only 12.5% of Africa, mostly in North Africa 
and South Africa, compared to 79.1% in Europe.23 
Indeed, studies from SSA referring to the availabili-
ty of PD drugs indicate that procurement of Par-
kinsonism drugs remains a difficult task. Winkler 
et al.31 stated that local pharmacies did not store L-
dopa. Furthermore, the nearest pharmacy with a 
supply of L-dopa available was approximately 300 
km away, thus introducing the additional cost of 
transportation, which most of the patients could not 
afford. In northern Nigeria, only 250/25 mg of L-
dopa was available to PD patients.32 Patients in their 
study who were able to afford ropinirole, pramipex-
ole and selegiline had these medications brought in 
from either the Middle East or Asia. Cubo et al.33 
compared the clinical profile of PD patients in Span-
ish and Cameroonian cohorts. They observed that 
the Cameroonian patients were intermittently treat-
ed, received L-dopa at lower doses, had less access 
to DAs, and used anticholinergics more frequently. 
The use of selegiline, rasagiline and DAs was noted 
mostly in the Spanish cohort. Bower et al.34 evalu-
ated the adequacy of treatment of PD patients seen 
in a movement disorders clinic in Ethiopia and re-
ported that only 59.6% of their patients received ad-
equate L-dopa over the study period.
Dotchin et al.35 investigated levodopa plus carbi-
dopa use in a three-year follow-up study in Hai in 
rural Tanzania. They reported that MAO-B inhibi-
tors and non-ergot DA were unavailable to PD pa-
tients. Bromocriptine, an ergot DA, was available as it 
was on the essential medicines list for the treatment 
of infertility. Ogunniyi,36 in his review titled, “Treat-
ment of Parkinsonism syndromes in developing 
countries,” observed that anticholinergics are among 
the most commonly used drugs and that the use of 
DAs is limited due to their high cost. Overall, the 
literature suggests that even when patients are able 
to be diagnosed with PD, treatment is irregular or 
non-existent, monitoring is limited, people resort 
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to local traditional healers for treatment, and mul-
tidisciplinary staff are rarely available.30 Mokaya et 
al.37 evaluated 48 drug outlets in Kenya and report-
ed that only 24 outlets, one of which was a public 
pharmacy, had L-dopa. Ergot-derived DAs and an-
ticholinergics were sold in 37 and 35 outlets, respec-
tively. Catechol-O-methyl transferase inhibitors were 
not available in any of the outlets. 
The cost burden of PD management in SSA
Although the estimated cost burden of the treat-
ment of PD varied by country, it was generally ac-
cepted that the cost burden was comparably high, 
making it difficult for most PD patients in SSA to 
maintain treatment. In Tanzania, Mshana et al.38 es-
timated that a one-month supply of PD drugs cost 
approximately 40,000 Tanzanian shillings, which is 
equivalent to approximately 33 US dollars (USD). 
In Ethiopia, Bower et al.34 reported that a monthly 
dose of 25 mg/250 mg levodopa/carbidopa cost an 
estimated 90 Ethiopian birr, which is equivalent to 
10.49 USD, and that the cost of an outpatient visit 
was approximately 0.66 USD. In Kenya, 100 tablets 
of L-dopa cost between 28.2 and 82.4 USD, with a 
mean cost of 48.2 USD.37
In many SSA settings, patients also pay for their 
transportation and for the consultation, thereby in-
creasing the cost of PD care.39 Cilia et al.40 observed 
that when they compared Ghanaian and Italian PD 
patients, levodopa was introduced to patients in 
Ghana later than to the Italian patients.
Neurosurgery and neuroradiology services
The estimated median number of neurosurgeons 
per 100,000 population is 0.01 in Africa compared 
to 1.02 in Europe and 0.39 per 100,000 population 
in the Western Pacific.23 Femi et al.32 reported that 
there were no neurosurgical services available for 
PD patients in a hospital-based clinical series in Ni-
geria. Cubo et al.33 reported that a lack of imaging 
facilities impaired their ability to differentiate sec-
ondary Parkinsonism from idiopathic PD among 
the patients they were evaluating in Cameroon. De-
chambenoit et al.,41 in his paper “Action Africa,” de-
scribed a lack of equipment and outdated operating 
theaters, with an absence of instruments for micro-
surgery and microscopes. He further stated that 
where neurosurgery institutes were available, they 
were inaccessible to 90% of the population due to a 
lack of health insurance systems. He also expressed 
the view that the prevailing economic conditions in 
SSA underlie the difficulties in equipping neurology 
and neurosurgical services, as well as the training of 
young doctors. His views regarding the lack of neu-
roimaging services were supported by Dotchin and 
Walker,39 who reported that dopamine transporter 
imaging, which is useful in differentiating PD from 
other tremor disorders, is unavailable in all settings 
in SSA. A summary of available standard manage-
ment of PD patients in SSA is presented in Table 5.
DISCUSSION
Genetics of PD in SSA
The findings of this review support the view that 
there is a possible unique genetic architecture of 
PD in the region because of the infrequent occur-
rence of mutations in established PD genes in SSA. 
This interpretation must, however, be viewed in the 
context that most of the studies in SSA had small 
sample sizes, with the largest being 205 subjects,12 
which makes the generalization of their findings 
difficult. The likelihood of discovering mutations in 
PARK genes might increase if considerably larger PD 
cohorts from SSA were to be analyzed. The identifi-
cation of mutations in established PD genes was doc-
umented only for Parkin among South African and 
Zambian cohorts from the 11 studies reviewed.9,42,43 
Both homozygous exon deletions9,43 and point muta-
tions9,42,43 were observed in these studies. No patho-
genic mutations were documented in studies screen-
ing for universally recognized PD genes such as α- 
synuclein, LRRK2, PINK1 and DJ-1 or genes of 
uncertain significance such as UCHL-1 in sub-Saha-
ran PD cohorts. The mean age at onset in most of 
the patients studied was above 50 years, while muta-
tions in PD genes are more commonly found in ear-
ly-onset PD, especially mutations in autosomal re-
cessively inherited genes such as Parkin, PINK1 and 
DJ-1.
Epidemiology
This review has described different rates of oc-
currence in both hospital- and community-based 
studies. Balogou et al.44 reported a prevalence rate of 
20/100,000 in their study, but Winkler et al.31 found 
no cases of PD among 1,569 community dwellers 
screened in rural Tanzania. The findings from other 
Parkinson's Disease in Sub-Saharan Africa
Williams U, et al.
www.e-jmd.org  61
populations are significantly higher than those re-
ported in SSA. Seo et al.45 in Korea reported a prev-
alence of 374/100,000 people > 18 years, while a 
prevalence of 146/100,000 was reported in Austra-
lia.46 These findings are very close to those of differ-
ent European studies, such as the prevalence of 144/ 
100,000 in Wales,47 128/100,000 in England48 and 
166/100,000 in Finland.49 Mayeux et al.50 published a 
slightly lower prevalence of 107/100,000 in the Unit-
ed States of America. The lower prevalence of PD 
in SSA could be due to different study methodolo-
gies and diagnostic criteria; the lower proportion of 
those older than 65 years in the SSA population; 
reduced access to health care; different health-seek-
ing behavior in the region; disease-related disability 
and cultural differences in the studied populations3; 
or the underdiagnosis of PD due to low social rec-
ognition, as typical symptoms of PD might be mis-
taken for symptoms of normal aging.51 Blancken-
berg et al.3 suggested that the decreased survival of 
PD patients due to a lack of drugs, unavailability of 
proper health care and other socio-economic chal-
Table 5. Summary of available standard management for PD patients in SSA
Item Key finding(s) Reference(s)
Availability of neurologist -  0.03 neurologists per 100,000 population in SSA compared to 0.07 in South East Asia 
and 4.84 per 100,000 population in Europe.
-  Until 2009, only one neurologist in Malawi with a population of 12 million.
- WHO23; WHO1
 
- Jung et al.24
Availability of geriatricians - Limited number of geriatricians
- No undergraduate & postgraduate training scheme in over 25 countries.
- Dotchin et al.25
PD Nurses - No neurology nurses in SSA as of 2006.
- First PD nurses training occurred in 2012.
- WHO23
- Walker26; Walker et al.27
Speech-language therapist 
(SLT)
-  No SLT services in Burundi, Burkina Faso, Cape Verde, Gambia, Guinea, 
Guinea Bissau, Liberia, Mali, Niger or Sierra Leone.
-  Speech-Language Therapy.COM; 
ASHA.org.28
OT and PT -  No regional studies evaluating OT/PT.
-  Active OT services registered in Botswana, Kenya, Malawi, Mauritius, Namibia, 
Nigeria, Rwanda, South Africa, Tanzania, Uganda, and Zimbabwe.
-  Only three registered occupational therapists caring for 160 million people.
-  Neuro-rehabilitation services present in only 81.2% of countries in SSA.
- History of OTARG to 201229
- WHO23
- WHO1
Availability of drugs -  In Africa, PD drugs mainly available in 12.5% of countries mostly in North Africa & 
South Africa compared to 79.1% in Europe.
-  Local pharmacies do not store levodopa in Tanzania.
-  Only 250/25 mg preparation of L-dopa available in Nigeria. Ropinirole, Pramipexole 
and Selegiline rarely available in the country.
-  Cameroonian patients have little access to dopamine agonist.
-  Only 59.6% of Ethiopian patients had adequate L-dopa.
-  Monoamine oxidase B inhibitors and non-ergot dopamine agonist not available 
in rural Tanzania.
-  Catechol-O-methyl transferase inhibitors were not available in any of the outlets in 
Kenya.
- WHO23
 
- Winkler et al.31
- Femi et al.32
 
- Cubo et al.33
- Bower et al.34
- Dotchin et al.35
 
- Mokaya et al.37
Cost of PD care -  Estimated cost of PD drug for one month in Tanzania was 33 US dollars.
-  Monthly cost of 250/25 mg levodopa/carbidopa in Ethiopia was 10.49 US dollars, 
while the cost equivalent of an outpatient visit was approximately 0.66 US dollars.
-  In Kenya, the average cost of 100 tablets of L-dopa was between 28.2 and 82.4 US 
dollars with an average of 48.2 US dollars.
-  PD patients have the added cost burden of paying for their transportation and 
consultation.
-  Mshana et al.38
-  Bower et al.34
 
-  Mokaya et al.37
 
-  Dotchin and Walker39
Neurosurgery & 
Neuroradiology Services
-  There are 0.01 neurosurgeons per 100,000 population in Africa compared to 1.02 in 
Europe and 0.39 per 100,000 population in Western pacific.
-  No neurosurgery service for PD patients in Nigeria.
-  Lack of neuroimaging service in Cameroon.
-  Dopamine imaging facility not available in SSA.
-  WHO23
 
-  Femi et al.32
-  Cubo et al.33
-  Dotchin and Walker39
PD: Parkinson’s disease, SSA: Sub-Saharan Africa, OT: occupational therapy, PT: physiotherapy.
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lenges might also result in a lower prevalence. The 
possibility of as yet undefined genetic and environ-
mental factors has also been suggested as a possible 
reason for the lower prevalence of PD in SSA.2 
It is difficult to draw much inference from, or to 
compare, hospital-based series in SSA because of 
the marked difference in methodology applied re-
garding diagnostic criteria, population characteris-
tics, and the estimated proportion reported, as some 
studies did not discriminate between idiopathic PD 
and other causes of secondary Parkinsonism. Door-
to-door surveys offer the best estimate of PD preva-
lence because they can detect as yet undiagnosed 
cases in the community among people with different 
health-seeking behaviors. However, a major chal-
lenge to this type of study is the high cost, which is 
inherently a major factor affecting research in SSA. 
Care availability and accessibility
Even when PD patients are able to be diagnosed, 
treatment is often non-existent or irregular; moni-
toring is limited; multidisciplinary teams are rarely 
available; and patients often turn to local traditional 
healers for treatment.13 The other challenge high-
lighted is the paucity of neurologists and other 
health care personnel caring for PD patients. The 
situation is the same for neurosurgeons, neuroradi-
ologists, geriatricians, PD nurses and other health 
care personnel. The treatment of patients after di-
agnosis is hampered by a lack of drugs, as these 
drugs are unavailable or unaffordable to the patients. 
Some of the available drugs are no longer used as 
first-line drug treatment in Europe and in other 
countries with a higher GDP and better-developed 
neurological services. For instance, anticholinergics 
and ergot DAs were used more than non-ergot DAs 
and MAO-B inhibitors in SSA. The impact of the 
high cost of PD treatment on access to PD drugs can-
not be over-emphasized in a region where almost 
50% of the population lives on less than 1.25 USD 
per day.52 The location of the few health facilities be-
ing far away from patients’ residences again increas-
es the financial burden on the patient, as they have 
to pay for the cost of transportation and consultation 
out of pocket in a region where only a small minority 
have health insurance.
CONCLUSION
This review has highlighted the challenges in-
volved in conducting genetic and epidemiologic 
studies in SSA. It has also been shown that the cur-
rently available care for PD patients is grossly inad-
equate. Large-scale, state-of-the-art genetic and ep-
idemiological studies will help to provide further 
insight into the role of genetic factors and other eti-
ological factors such as toxin exposure in PD in 
SSA. Collaborative studies using the same method-
ology and staffed by personnel with comparable 
training will help establish a data set that could then 
be used to compare the PD prevalence rates across 
different populations. The establishment of mini-
mal consensus management guidelines may help to 
improve the consistency and quality of care. Inter-
national assistance is needed regarding improved 
public awareness of neurological diseases, training 
of health care workers, provision of affordable drugs 
and facilities for PD treatment and the monitoring 
of PD patients in the region.
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